Dannielle Appelhans is CEO and President of Rubius Therapeutics, Inc.. Currently has a direct ownership of 0 shares of RUBY, which is worth approximately $0. The most recent transaction as insider was on Feb 24, 2023, when has been sold 10,385 shares (Common Stock) at a price of $0.13 per share, resulting in proceeds of $1,350. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0
0% 3M change
0% 12M change
Total Value Held $0

Dannielle Appelhans Transaction History

Date Transaction Value Shares Traded Shares Held Form
Feb 24 2023
SELL
Open market or private sale
$1,350 $0.13 p/Share
10,385 Reduced 100.0%
0 Common Stock
Feb 01 2023
SELL
Open market or private sale
$969 $0.25 p/Share
3,878 Reduced 27.19%
10,385 Common Stock
Jan 31 2023
BUY
Exercise of conversion of derivative security
-
7,500 Added 34.46%
14,263 Common Stock
Aug 10 2022
SELL
Open market or private sale
$4,590 $0.8 p/Share
5,737 Reduced 45.9%
6,763 Common Stock
Aug 09 2022
BUY
Exercise of conversion of derivative security
-
12,500 Added 50.0%
12,500 Common Stock

Also insider at

GBIO
Generation Bio Co. Healthcare
DA

Dannielle Appelhans

CEO and President
Cambridge, MA

Track Institutional and Insider Activities on RUBY

Follow Rubius Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RUBY shares.

Notify only if

Insider Trading

Get notified when an Rubius Therapeutics, Inc. insider buys or sells RUBY shares.

Notify only if

News

Receive news related to Rubius Therapeutics, Inc.

Track Activities on RUBY